These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35168879)

  • 1. Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma.
    Andrews JR; Lohse CM; Boorjian SA; Leibovich BC; Thompson H; Costello BA; Bhindi B
    Urol Oncol; 2022 Apr; 40(4):166.e1-166.e8. PubMed ID: 35168879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
    Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
    Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
    Bhindi B; Graham J; Wells JC; Bakouny Z; Donskov F; Fraccon A; Pasini F; Lee JL; Basappa NS; Hansen A; Kollmannsberger CK; Kanesvaran R; Yuasa T; Ernst DS; Srinivas S; Rini BI; Bowman I; Pal SK; Choueiri TK; Heng DYC
    Eur Urol; 2020 Oct; 78(4):615-623. PubMed ID: 32362493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach.
    Liu WK; Lam JM; Butters T; Grant M; Jackson-Spence F; Bex A; Powles T; Szabados B
    World J Urol; 2020 Dec; 38(12):3199-3205. PubMed ID: 32128610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma.
    Roussel E; Verbiest A; Milenkovic U; Van Cleynenbreugel B; Van Poppel H; Joniau S; Beuselinck B; Albersen M
    Scand J Urol; 2020 Dec; 54(6):493-499. PubMed ID: 32924729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Position of cytoreductive nephrectomy in the setting of metastatic renal cell carcinoma patients: does the CARMENA trial lead to a paradigm shift?
    Dariane C; Timsit MO; Méjean A
    Bull Cancer; 2018 Dec; 105 Suppl 3():S229-S234. PubMed ID: 30595151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?
    Larcher A; Wallis CJD; Bex A; Blute ML; Ficarra V; Mejean A; Karam JA; Van Poppel H; Pal SK
    Eur Urol Oncol; 2019 Jul; 2(4):365-378. PubMed ID: 31109902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy.
    Gross EE; Li M; Yin M; Orcutt D; Hussey D; Trott E; Holt SK; Dwyer ER; Kramer J; Oliva K; Gore JL; Schade GR; Lin DW; Tykodi SS; Hall ET; Thompson JA; Parikh A; Yang Y; Collier KA; Miah A; Mori-Vogt S; Hinkley M; Mortazavi A; Monk P; Folefac E; Clinton SK; Psutka SP
    Urol Oncol; 2023 Jan; 41(1):51.e25-51.e31. PubMed ID: 36441070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting.
    Ljungberg B; Sundqvist P; Lindblad P; Kjellman A; Thorstenson A; Hellström M; Kröger Dahlin BI; Thomasson M; Harmenberg U; Lundstam S
    Scand J Urol; 2020 Dec; 54(6):487-492. PubMed ID: 32897123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy.
    Hahn AW; Kotecha RR; Viscuse PV; Pieretti AC; Wiele AJ; Jonasch E; Lee CH; Gao J; Zurita AJ; Shah AY; Campbell MT; Sharma P; Motzer RJ; Russo P; Wood CG; Tannir NM; Voss MH; Karam JA; Hakimi AA; Msaouel P
    Eur Urol Focus; 2023 Sep; 9(5):734-741. PubMed ID: 36863962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Takemura K; Ernst MS; Navani V; Wells JC; Bakouny Z; Donskov F; Basappa NS; Wood LA; Meza L; Pal SK; Szabados B; Powles T; Beuselinck B; McKay RR; Lee JL; Ernst DS; Kapoor A; Yuasa T; Choueiri TK; Heng DYC
    Eur Urol Oncol; 2024 Jun; 7(3):501-508. PubMed ID: 37914579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Bakouny Z; El Zarif T; Dudani S; Connor Wells J; Gan CL; Donskov F; Shapiro J; Davis ID; Parnis F; Ravi P; Steinharter JA; Agarwal N; Alva A; Wood L; Kapoor A; Ruiz Morales JM; Kollmannsberger C; Beuselinck B; Xie W; Heng DYC; Choueiri TK
    Eur Urol; 2023 Feb; 83(2):145-151. PubMed ID: 36272943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological Response and Outcomes in Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Immunotherapy-Based Therapies and Undergoing Deferred Cytoreductive Nephrectomy (CN).
    Gunenc D; Issa W; Gerald T; Zhou Q; Zhang S; Ibezue IC; Bhanvadia R; Tachibana I; Brugarolas J; Hammers H; Qin Q; Kapur P; Woldu S; Gaston K; Lotan Y; Cadeddu J; Wang AZ; Margulis V; Zhang T
    Clin Genitourin Cancer; 2024 Oct; 22(5):102177. PubMed ID: 39218752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in immune-oncology era (SEVURO-CN): study protocol for a multi-center, prospective, randomized trial.
    Park JS; Kim J; Jeon J; Lee J; Jang WS; Lee SH; Han WK; Choi YD; Koo KC; Cho KS; Chung BH; Ham WS
    Trials; 2024 Jul; 25(1):447. PubMed ID: 38961439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies.
    Claeys T; Lumen N; Kumps C; Praet M; De Meerleer G; Rottey S; Ost P; Devisschere P; Villeirs G; Fonteyne V; Decaestecker K
    Urol Oncol; 2017 Apr; 35(4):152.e13-152.e22. PubMed ID: 28153420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.
    de Bruijn R; Wimalasingham A; Szabados B; Stewart GD; Welsh SJ; Kuusk T; Blank C; Haanen J; Klatte T; Staehler M; Powles T; Bex A
    Eur Urol Oncol; 2020 Apr; 3(2):168-173. PubMed ID: 31956080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic model of upfront cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors and/or targeted agents.
    Teishima J; Goto K; Sekino Y; Mita K; Hayashi T; Hasegawa Y; Kato M; Kajiwara M; Shigeta M; Maruyama S; Kadonishi Y; Fujiwara S; Kobayashi K; Asano K; Hinata N
    Int Urol Nephrol; 2022 Jun; 54(6):1225-1232. PubMed ID: 35314918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Real-World Multi-Institutional Analysis.
    Ghatalia P; Handorf EA; Geynisman DM; Deng M; Zibelman MR; Abbosh P; Anari F; Greenberg RE; Viterbo R; Chen D; Smaldone MC; Kutikov A; Uzzo RG
    J Urol; 2022 Jul; 208(1):71-79. PubMed ID: 35212574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Jpn J Clin Oncol; 2021 Feb; 51(2):296-304. PubMed ID: 32989464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.